Endometriosis Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The endometriosis market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to delayed diagnosis and increased awareness, advances in laparoscopic surgery, hormonal therapies, patient advocacy and support groups.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, global expansion of women's healthcare. Major trends in the forecast period include patient-centered care, precision medicine, virtual care and telemedicine, fertility preservation.

The escalating prevalence of ovarian cancer is poised to be a driving force behind the anticipated growth of the endometriosis market. Ovarian cancer, a malignancy originating in the ovaries - vital female reproductive organs responsible for egg production and hormone secretion - is intrinsically linked to endometriosis. This condition heightens the risk of developing certain ovarian cancer subtypes, notably the endometrioid and precise cell cancer subtypes characterized by elevated estrogen concentrations, which can elevate ovarian cancer risk. As an illustration, data from the American Cancer Society in January 2023 projects around 19,710 new cases of ovarian cancer among women in the United States for 2023. Additionally, the Ovarian Cancer Research Alliance, a U.S.-based not-for-profit organization, reported 12,810 ovarian cancer-related fatalities in 2022, with a rise to 13,270 expected in 2023. Consequently, the surge in ovarian cancer incidence is a driving factor behind the expansion of the endometriosis market.

The upswing in government funding is anticipated to propel the growth of the endometriosis market. Government funding encompasses financial support provided to non-government entities, wherein all or a portion of the financial backing is supplied by government entities. Typically channeled through grants and contracts, government funding is instrumental in advancing endometriosis research, benefitting individual researchers and research institutions conducting clinical studies. As an example, in March 2022, the U.S. federal government unveiled a commitment of $92 million in funding for the National Institute of Child Health and Human Development (NICHD). The Department of Defense's Peer-Reviewed Medical Research Programme (PRMRP) continues to receive substantial support with $370 million in funding for endometriosis research. Consequently, the upsurge in government funding plays a pivotal role in propelling the growth of the endometriosis market.

Prominent companies engaged in the endometriosis market are placing their focus on the development of innovative medications, including Myfembree, and securing approvals to introduce fresh treatment options for patients. The advent of novel medications for endometriosis addresses a previously unmet need for effective treatments. For instance, in August 2022, Myovant Sciences GmbH, a Switzerland-based biopharmaceutical company, in collaboration with Pfizer Inc., a U.S.-based pharmaceutical industry company, secured approval from the U.S. Food and Drug Administration (FDA) for Myfembree. This medication is designed for the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree is a once-daily pill that combines three vital components such as relugolix, estradiol, and norethindrone acetate, offering proven relief to premenopausal women with two indications in a single pill. This presents an alternative treatment choice for women who cannot or prefer not to use hormone therapy.

In February 2022, Theramex, a U.K.-based pharmaceutical company specializing in women's health, particularly in contraception, fertility, menopause, and osteoporosis, entered a partnership with ObsEva SA. The collaboration aims to commercialize Linzagolix, an oral GnRH antagonist, for women experiencing uterine fibroids and endometriosis-related pain, with potential royalties reaching up to USD 80.03 million (EUR 72.75 million). ObsEva SA, a Switzerland-based biopharmaceutical company, focuses on developing and commercializing innovative therapies for women’s reproductive health and pregnancy.

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

North America was the largest region in the endometriosis market in 2024. The regions covered in endometriosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endometriosis market consists of revenues earned by entities by providing services such as laparoscopy, nutritional counseling, physical therapy, diagnostic laparoscopy, fertility treatment, surgical interventions and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The endometriosis market also includes sales of birth control pills, patches and vaginal rings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Endometriosis is a chronic medical condition characterized by the growth of tissue similar to the uterine lining (endometrium) outside the uterus. This condition often results in severe pelvic pain and can complicate fertility, significantly impacting an individual's overall well-being and ability to conceive.

Endometriosis presents in various forms, including superficial peritoneal lesions, endometrioma, deeply infiltrating endometriosis, and other less common manifestations. Superficial peritoneal lesions denote a specific type of abnormal tissue growth associated with endometriosis and typically necessitate treatments like hormonal therapy and pain management. Several drugs and therapies are available for managing this condition, including oral contraceptives, progestins, nonsteroidal anti-inflammatory drugs (NSAIDs), GnRH analogs, levonorgestrel-releasing intrauterine devices (LNR-IUDs), among others. These treatments are administered by different healthcare end-users, such as hospitals, homecare services, specialty centers, and others.

The endometriosis market research report is one of a series of new reports that provides endometriosis market statistics, including endometriosis industry global market size, regional shares, competitors with an endometriosis market share, detailed endometriosis market segments, market trends and opportunities and any further data you may need to thrive in the endometriosis industry. This endometriosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.